

sector providers offer an array of value-added cash services that the Federal Reserve Bank offices do not provide. The revised policy also clarifies that armored carriers may be designated as endpoints. The Board's revised policy, therefore, does not adversely affect the ability of depository institutions or service providers to compete with the Federal Reserve Banks to provide cash services.

#### V. Federal Reserve Cash Service Access Policy

The Board has adopted the following Federal Reserve cash access policy:

1. *Number of endpoints eligible for free cash access.* Each depository institution can designate up to ten endpoints to receive free cash access (deposit and order) service from each Reserve Bank office. A depository institution may not designate an endpoint to receive free cash access from more than one Reserve Bank office. A designated endpoint may be a branch, head office, a money room and/or an armored carrier used by the depository institution to provide cash services. Individual ATM locations are not eligible for designation as endpoints. If a depository institution uses an armored carrier to service ATMs, the armored carrier may be designated as an endpoint.

Beyond the ten endpoints, Reserve Bank offices will provide free cash access to endpoints whose volumes exceed a specified threshold. Each Reserve Bank office will set a "high bundle threshold," within the range of fifty to one hundred bundles, to accommodate the needs of the geographic area being serviced within that Federal Reserve office territory. If a depository institution receives free access for more than ten endpoints, each endpoint must meet the high bundle threshold.

2. *Frequency of access.* Normal free access for each designated endpoint of the depository institution will be one deposit and one order per week. Access more frequent than once per week will be available free of charge to each designated endpoint whose volume exceeds a twenty-bundle aggregate threshold and that satisfies the local Reserve Bank office's denomination bundle standard.

3. *Priced access.* Reserve Bank offices may choose to accommodate additional access where the demand exists subject to the constraints of the physical facilities at each Reserve Bank office. Reserve Banks must price access to cash services beyond the free service described above, if offered.

4. *Delegation of authority.* The director of the Division of Reserve Bank Operations and Payment Systems, under delegated authority, may (1) approve changes in the base number of free endpoints and the volume thresholds; (2) waive the policy for a limited period if warranted by special circumstances, such as a natural disaster or the introduction of new currency; and (3) interpret the cash access policy. The director may further delegate this authority to interpret the policy to the Federal Reserve Banks' Financial Services Policy Committee.

By order of the Board of Governors of the Federal Reserve System, March 5, 1998.

**William W. Wiles,**

*Secretary of the Board.*

[FR Doc. 98-6137 Filed 3-9-98; 8:45 am]

BILLING CODE 6210-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Request for Nominations for Members on Public Advisory Committees; Pharmacy Compounding Advisory Committee

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is requesting nominations for 15 members to serve on the Pharmacy Compounding Advisory Committee in the Center for Drug Evaluation and Research. Elsewhere in this issue of the **Federal Register**, FDA is publishing a final rule announcing the establishment of this committee.

FDA has special interest in ensuring that women, minority groups, and the physically challenged are adequately represented on advisory committees and, therefore, extends particular encouragement to nominations for appropriately qualified female, minority, or physically challenged candidates.

**DATES:** Nominations should be received on or before April 9, 1998.

**ADDRESSES:** All nominations for membership, except for the representative of a consumer organization, should be sent to Kimberly L. Topper (address below). All nominations for the representative of a consumer organization should be sent to Annette J. Funn (address below).

**FOR FURTHER INFORMATION CONTACT:**

Regarding all nominations for membership, except for the

representative of a consumer organization: Kimberly L. Topper, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455.

Regarding all nominations for the representative of a consumer organization: Annette J. Funn, Office of Consumer Affairs (HFE-88), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5006.

**SUPPLEMENTARY INFORMATION:** On November 21, 1997, the President signed the Food and Drug Administration Modernization Act of 1997 (Pub. L. 105-115) (the Modernization Act). Section 127 of the Modernization Act added section 503A to the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a). Section 503A directs FDA to issue regulations relating to the application of Federal law to the practice of pharmacy compounding. To assist the agency in preparing these regulations, Congress directed FDA to convene and consult an advisory committee that will include representatives of the National Association of Boards of Pharmacy (NABP), the United States Pharmacopoeia (U.S.P.), pharmacy, physician, and consumer organizations, as well as other experts selected by the agency. Accordingly, FDA is requesting nominations for 15 members to serve on the Pharmacy Compounding Advisory Committee.

#### Function

The function of the committee is to provide advice on scientific, technical, and medical issues concerning drug compounding by licensed practitioners and to make appropriate recommendations to the Commissioner of Food and Drugs.

#### Criteria for Members

Persons nominated for membership should have expertise in one or more of the following fields: Pharmaceutical compounding, the practices of pharmacies specializing in compounding, the practices of general retail pharmacies, the practices of hospital pharmacies, fields of medicine in which compounding drugs or the use of compounded drugs is relatively common, pharmaceutical manufacturing, clinical toxicology, clinical pharmacology, chemistry, and related specialties. The committee will include one representative of the NABP, one representative of the U.S.P., one representative of a pharmacy organization, one representative of a

physician organization, one representative of a consumer organization, and one representative of the pharmaceutical manufacturing industry. The term of office is 4 years, except that initial appointments will be staggered to permit an orderly rotation of membership.

#### Nomination Procedures

Interested persons may nominate one or more qualified persons for membership on the advisory committee. Nominations shall state that the nominee is willing to serve as a member of the advisory committee and appears to have no conflict of interest that would preclude committee membership. Potential candidates will be asked by FDA to provide detailed information concerning such matters as financial holdings, consultancies, and research grants or contracts to permit evaluation of possible sources of conflict of interest.

Selection of a representative of a consumer organization is conducted through procedures which include use of a consortium of consumer organizations which has the responsibility for screening, interviewing, and recommending candidates for the agency's selection. Representatives of a consumer organization must possess appropriate qualifications to understand and contribute to the committee's work.

Selection of the member representing pharmaceutical manufacturing industry interests will be made in accordance with the advisory committee member selection process (21 CFR 14.80).

The NABP and the U.S.P. will be sent letters requesting nominations for their representatives on the advisory committee.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. App. 2), section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a), section 904 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 394) as amended by the Food and Drug Administration Revitalization Act (Pub. L. 101-635), and 21 CFR part 14, relating to advisory committees.

Dated: March 3, 1998.

**Michael A. Friedman,**

*Deputy Commissioner for Operations.*

[FR Doc. 98-6152 Filed 3-9-98; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Biological Response Modifiers Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

*Name of Committee:* Biological Response Modifiers Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA regulatory issues.

*Date and Time:* The meeting will be held on March 24, 1998, 8:30 a.m. to 5 p.m.

*Location:* DoubleTree Hotel, 1750 Rockville Pike, Rockville, MD.

*Contact Person:* Gail M. Dapolito or Rosanna L. Harvey, Center for Biologics Evaluation and Research (HFM-21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12389. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* The committee will discuss CellPro Inc.'s Ceparate® SC System for use in processing autologous peripheral blood stem cells. The committee will also hear short briefings on research programs in the Laboratory of Cellular Immunology and the Laboratory of Developmental Biology.

*Procedure:* On March 24, 1998, from 8:30 a.m. to 1:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by March 17, 1998. Oral presentations from the public will be scheduled between approximately 8:30 a.m. and 9:30 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 17, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

*Closed Committee Deliberations:* On March 24, 1998, from 1:30 p.m. to 3:45 p.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)). This portion of the meeting will be closed to discuss current investigational new drug application submissions under FDA review. On March 24, 1998, from 3:45 p.m. to 5 p.m., the meeting will be closed to review data of a personal nature where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). This portion of the meeting will be closed to permit discussion of this information.

FDA regrets that it was unable to publish this notice 15 days prior to the March 24, 1998, Biological Response Modifiers Advisory Committee meeting. Because the agency believes there is some urgency to bring these issues to public discussion and qualified members of the Biological Response Modifiers Advisory Committee were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: March 5, 1998.

**Michael A. Friedman,**

*Deputy Commission for Operations.*

[FR Doc. 98-6210 Filed 3-6-98; 12:21 pam]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### National Consumer Forum; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of meeting.

The Food and Drug Administration's (FDA) Office of Consumer Affairs (OCA) is announcing the second in a series of National Consumer Forums. The forums provide an opportunity for FDA to engage in an open dialogue with consumers and patient advocates on a variety of regulatory and consumer-oriented issues.

*Date and Time:* The meeting will be held on March 20, 1998, from 1:30 p.m. to 3:30 p.m.

*Location:* The meeting will be held at the Washington Plaza Hotel,